Synergism of eravacycline combined with other antimicrobial agents against carbapenem-resistant Enterobacteriaceae and Acinetobacter baumannii

Synergism of eravacycline combined with other antimicrobial agents against carbapenem-resistant Enterobacteriaceae and Acinetobacter baumannii

ABSTRACT: Objectives: This study aimed to investigate the synergistic activity of eravacycline combined with other antimicrobial agents against carbapenem-resistant Enterobacteriaceae and Acinetobacter baumannii collected from China. Methods: Sixty carbapenem-resistant strains, including 20 Escheri...

Full description

Bibliographic Details
Main Authors:	Yun Li, Lanqing Cui, Feng Xue, Qing Wang, Bo Zheng
Format:	Article
Language:	English
Published:	Elsevier 2022-09-01
Series:	Journal of Global Antimicrobial Resistance
Subjects:	Carbapenem resistance Gram-negative isolates Eravacycline In vitro Synergy
Online Access:	http://www.sciencedirect.com/science/article/pii/S2213716522001230

Similar Items

Clinical Outcomes of Eravacycline in Patients Treated Predominately for Carbapenem-Resistant Acinetobacter baumannii
by: Sara Alosaimy, et al.
Published: (2022-10-01)

Antibacterial Activity of Eravacycline Against Carbapenem-Resistant Gram-Negative Isolates in China: An in vitro Study
by: Zou X, et al.
Published: (2023-04-01)

Emergence of eravacycline heteroresistance in carbapenem-resistant Acinetobacter baumannii isolates in China
by: Yi-tan Li, et al.
Published: (2024-03-01)

In Vitro Activity of Eravacycline against Carbapenemase-Producing Gram-Negative Bacilli Clinical Isolates in Central Poland
by: Małgorzata Brauncajs, et al.
Published: (2023-06-01)

In vitro susceptibility of common Enterobacterales to eravacycline in Taiwan
by: Chun-Fu Huang, et al.
Published: (2023-04-01)

In vitro activity of eravacycline and comparators against Gram-negative and Gram-positive bacterial isolates collected from patients globally between 2017 and 2020
by: Stephen Hawser, et al.
Published: (2023-06-01)

Efficacy and safety of eravacycline: A meta-analysis
by: Khalid Eljaaly, et al.
Published: (2021-03-01)

In vitro activity of cefiderocol, cefepime/enmetazobactam, cefepime/zidebactam, eravacycline, omadacycline, and other comparative agents against carbapenem-non-susceptible Pseudomonas aeruginosa and Acinetobacter baumannii isolates associated from bloodstream infection in Taiwan between 2018–2020
by: Po-Yu Liu, et al.
Published: (2022-10-01)

Omadacycline, Eravacycline, and Tigecycline Express Anti-Mycobacterium abscessus Activity In Vitro
by: Anqi Li, et al.
Published: (2023-06-01)

AdeABC Efflux Pump Controlled by AdeRS Two Component System Conferring Resistance to Tigecycline, Omadacycline and Eravacycline in Clinical Carbapenem Resistant Acinetobacter nosocomialis
by: Yi-Tzu Lee, et al.
Published: (2020-11-01)

Peptidoglycan Recycling Promotes Outer Membrane Integrity and Carbapenem Tolerance in Acinetobacter baumannii
by: Nowrosh Islam, et al.
Published: (2022-06-01)

Evaluating the Efficacy of Eravacycline and Omadacycline against Extensively Drug-Resistant <i>Acinetobacter baumannii</i> Patient Isolates
by: Manas S. Deolankar, et al.
Published: (2022-09-01)

In Vitro Synergy Testing of Eravacycline in Combination with Clarithromycin and Rifabutin against Mycobacterium abscessus Complex
by: Ka Lip Chew, et al.
Published: (2021-09-01)

Antimicrobial Activity of a Repurposed Harmine-Derived Compound on Carbapenem-Resistant Acinetobacter baumannii Clinical Isolates
by: Anke Breine, et al.
Published: (2022-01-01)

Evaluation of In Vitro Activity of Double-Carbapenem Combinations against KPC-2-, OXA-48- and NDM-Producing <i>Escherichia coli</i> and <i>Klebsiella pneumoniae</i>
by: Lisa Allander, et al.
Published: (2022-11-01)

Integrative analysis of outer membrane vesicles proteomics and whole-cell transcriptome analysis of eravacycline induced Acinetobacter baumannii strains
by: DineshKumar Kesavan, et al.
Published: (2020-02-01)

In vitro activities of Eravacycline against 336 isolates collected from 2012 to 2016 from 11 teaching hospitals in China
by: Chunjiang Zhao, et al.
Published: (2019-06-01)

Zidebactam restores sulbactam susceptibility against carbapenem-resistant Acinetobacter baumannii isolates
by: Jose Cedano, et al.
Published: (2022-07-01)

Detection and characterization of eravacycline heteroresistance in clinical bacterial isolates
by: Yingfeng Zhang, et al.
Published: (2024-03-01)

Carbapenem-Resistant Enterobacteriaceae Posing a Dilemma in Effective Healthcare Delivery
by: Angus Nnamdi Oli, et al.
Published: (2019-09-01)

In Vitro Activities of Colistin and Sitafloxacin Combinations against Multidrug-, Carbapenem-, and Colistin-Resistant <i>Acinetobacter baumannii</i> Using the Broth Microdilution Checkerboard and Time-Kill Methods
by: Vipavee Rodjun, et al.
Published: (2020-08-01)

In Vitro Activities of Aztreonam-Avibactam, Eravacycline, Cefoselis, and Other Comparators against Clinical Enterobacterales Isolates: a Multicenter Study in China, 2019
by: Jiawei Chen, et al.
Published: (2023-06-01)

Is It Possible to Eradicate Carbapenem-Resistant <i>Acinetobacter baumannii</i> (CRAB) from Endemic Hospitals?
by: Filippo Medioli, et al.
Published: (2022-07-01)

A retrospective, multicentre evaluation of eravacycline utilisation in community and academic hospitals
by: Athena L.V. Hobbs, et al.
Published: (2022-06-01)

In-Vitro Evaluation of Different Antimicrobial Combinations with and without Colistin Against Carbapenem-Resistant Acinetobacter Baumannii
by: Alessandra Oliva, et al.
Published: (2019-03-01)

In Vitro Antimicrobial Activities of Tigecycline, Eravacycline, Omadacycline, and Sarecycline against Rapidly Growing Mycobacteria
by: Tingting Zhang, et al.
Published: (2023-02-01)

Development of Resistance to Eravacycline by Klebsiella pneumoniae and Collateral Sensitivity-Guided Design of Combination Therapies
by: Congjuan Xu, et al.
Published: (2022-10-01)

Environmental colonization and transmission of carbapenem-resistant enterobacteriaceae and carbapenem-resistant Acinetobacter baumannii in intensive care unit
by: Priyal P Trivedi, et al.
Published: (2023-01-01)

Synergistic Activity of Cefiderocol in Combination with Piperacillin-Tazobactam, Fosfomycin, Ampicillin-Sulbactam, Imipenem-Relebactam and Ceftazidime-Avibactam against Carbapenem-Resistant Gram-Negative Bacteria
by: Marta Palombo, et al.
Published: (2023-05-01)

Eravacycline, the first four years: health outcomes and tolerability data for 19 hospitals in 5 U.S. regions from 2018 to 2022
by: Ashlan J. Kunz Coyne, et al.
Published: (2024-01-01)

Ceftazidime-avibactam/aztreonam combination synergy against carbapenem-resistant Gram-negative isolates: In vitro study
by: Reena Rajan, et al.
Published: (2024-01-01)

A Cohort Study of the Impact of Carbapenem-Resistant <italic toggle="yes">Enterobacteriaceae</italic> Infections on Mortality of Patients Presenting with Sepsis
by: Sabrina Sabino, et al.
Published: (2019-04-01)

Emergence of Carbapenem-Resistant Gram-Negative Isolates in Hospital Settings in Djibouti
by: Ayan Ali Ragueh, et al.
Published: (2023-06-01)

The threat of carbapenem-resistant gram-negative bacteria in a Middle East region
by: Davoudi-Monfared E, et al.
Published: (2018-10-01)

Epidemiological characteristics of carbapenem-resistant Enterobacteriaceae and carbapenem-resistant Acinetobacter baumannii in a tertiary referral hospital in Korea
by: Sollan Kang, et al.
Published: (2022-06-01)

Bibliometric Examination of Global Scientific Research about Carbapenem-Resistant <i>Acinetobacter Baumannii</i> (CRAB)
by: Himanshu Jangid, et al.
Published: (2023-11-01)

In vitro antimicrobial activity and resistance mechanisms of the new generation tetracycline agents, eravacycline, omadacycline, and tigecycline against clinical Staphylococcus aureus isolates
by: Weiliang Zeng, et al.
Published: (2022-11-01)

Mechanism of Eravacycline Resistance in Clinical Enterococcus faecalis Isolates From China
by: Zewen Wen, et al.
Published: (2020-05-01)

In vitro Antimicrobial Activity and Dose Optimization of Eravacycline and Other Tetracycline Derivatives Against Levofloxacin-Non-Susceptible and/or Trimethoprim-Sulfamethoxazole-Resistant Stenotrophomonas maltophilia
by: Wu J, et al.
Published: (2023-09-01)

A Real-World Assessment of Clinical Outcomes and Safety of Eravacycline: A Novel Fluorocycline
by: Nicholas Van Hise, et al.
Published: (2020-10-01)